Tempus AI, Inc. $TEM Shares Bought by Washington Trust Advisors Inc.

Key Points

• Washington Trust Advisors increased its Tempus AI stake by 35.7% in the third quarter, purchasing 31,873 additional shares and bringing its holdings to 121,039 shares valued at approximately $9.9 million.
• Other institutional investors also accumulated shares, with institutional ownership reaching 24.22%. However, insiders sold 1.28 million shares worth about $80.4 million over the past three months, including a $19.4 million sale by CEO Eric Lefkofsky.
• Tempus AI shares rose 6.0% to $67.61, while analysts maintained a mixed outlook: the stock has a consensus “Hold” rating and an average price target of $72.37. The company reported better-than-expected quarterly results, including $382.5 million in revenue and an adjusted loss of $0.04 per share.

Washington Trust Advisors Inc. boosted its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 35.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 121,039 shares of the company's stock after buying an additional 31,873 shares during the quarter. Washington Trust Advisors Inc. owned approximately 0.07% of Tempus AI worth $9,913,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of TEM. Guardian Partners Inc. lifted its holdings in Tempus AI by 8.3% during the third quarter. Guardian Partners Inc. now owns 2,600 shares of the company's stock worth $213,000 after buying an additional 200 shares during the period. Quadrant Capital Group LLC purchased a new position in shares of Tempus AI in the 3rd quarter valued at $265,000. Blue Jean Financial LLC purchased a new position in shares of Tempus AI in the 3rd quarter valued at $3,683,000. Generali Investments Management Co LLC purchased a new position in shares of Tempus AI in the 3rd quarter valued at $502,000. Finally, IFP Advisors Inc increased its holdings in shares of Tempus AI by 44.1% in the 3rd quarter. IFP Advisors Inc now owns 3,687 shares of the company's stock valued at $302,000 after acquiring an additional 1,128 shares during the period. Institutional investors own 24.22% of the company's stock.

Insider Buying and Selling at Tempus AI

In other news, CEO Eric Lefkofsky sold 250,000 shares of the company's stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the transaction, the chief executive officer owned 100,000 shares in the company, valued at $7,747,000. This represents a 71.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nadja West sold 3,000 shares of the stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $69.00, for a total transaction of $207,000.00. Following the completion of the transaction, the director directly owned 31,981 shares of the company's stock, valued at $2,206,689. The trade was a 8.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,280,965 shares of company stock valued at $80,397,564. Insiders own 24.26% of the company's stock.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Needham reiterates Buy rating: Needham & Company maintained its Buy recommendation and set a $75 price target, implying roughly 11% upside from the cited share price. The call reinforces Wall Street support for Tempus’ growth outlook. Needham analyst recommendations
• Positive Sentiment: Expanded Bristol Myers Squibb relationship: Tempus announced multi-year oncology and AI-data agreements with Bristol Myers Squibb, a major pharmaceutical validation of its clinical-data platform. The collaboration could support recurring data-related revenue and increase Tempus’ role in drug development. Tempus expands Bristol Myers partnership
• Positive Sentiment: New Pathos AI partnership expands neuroscience reach: Tempus is partnering with Pathos AI and Bristol Myers Squibb on medical research, including neurology and neuroscience applications. Pathos’ $237 million financing and approximately $3 billion valuation may increase the visibility and perceived strategic value of Tempus’ data and AI capabilities. Tempus expands neurology data partnership
• Positive Sentiment: Investor commentary remains constructive: Recent analyses describe Tempus as less risky than previously viewed and highlight its proprietary healthcare-data advantage, as well as its involvement with Moderna’s cancer-vaccine efforts. These opinions add momentum, although they are not company financial results. Tempus AI less risky analysis
• Neutral Sentiment: Tempus remains unprofitable and carries elevated volatility, so investors will likely focus on whether these partnerships translate into sustained revenue growth and improved margins. The company’s recent quarterly results showed stronger-than-expected revenue and a narrower-than-expected loss, but execution remains important.

Tempus AI Stock Up 6.0%

Shares of Tempus AI stock traded up $3.80 during trading on Friday, reaching $67.61. The company's stock had a trading volume of 4,678,111 shares, compared to its average volume of 6,570,224. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The company has a market cap of $12.20 billion, a price-to-earnings ratio of -46.95 and a beta of 3.54. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $93.38. The company has a 50-day simple moving average of $69.24 and a two-hundred day simple moving average of $57.19.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%. The firm's quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.22) EPS. As a group, equities analysts forecast that Tempus AI, Inc. will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on TEM shares. Canaccord Genuity Group upped their price objective on Tempus AI from $80.00 to $95.00 and gave the stock a "buy" rating in a research note on Monday, October 12th. Lake Street Capital lowered Tempus AI to a "hold" rating in a research note on Monday, July 20th. Wall Street Zen upgraded shares of Tempus AI from a "sell" rating to a "hold" rating in a report on Saturday, July 25th. Guggenheim boosted their target price on shares of Tempus AI from $65.00 to $92.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. Finally, Stifel Nicolaus decreased their price target on shares of Tempus AI from $60.00 to $50.00 and set a "hold" rating for the company in a research report on Monday, August 3rd. Eleven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $72.37.

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.